{"links":{"html":"https://www.erudio.com/reports/rapchem-nct01279304","json":"https://www.erudio.com/reports/rapchem-nct01279304.json","markdown":"https://www.erudio.com/reports/rapchem-nct01279304.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rapchem-01279304"}},"request":"https://www.erudio.com/contact?report=rapchem-01279304"},"offer":{"cited_commentary_sources":30,"verified_hcp_statements":106,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":17,"optional":true,"price_per_verified_person_usd":15,"price_usd":255,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rapchem-nct01279304"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rapchem-01279304","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rapchem-nct01279304","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T03:46:59.926639Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":18,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":16,"title":"Primary endpoint: locoregional recurrence rate"},{"claim_count":14,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":17,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":18,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":11,"title":"Safety and tolerability"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":11,"title":"Evidence thresholds, pragmatic registries and practice uptake"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":5,"title":"Axillary surgery, treatment balance and guideline adherence"},{"claim_count":23,"coverage":"discussed","id":"A3","source_count":8,"title":"Tumor biology, late recurrence and endocrine-treatment explanations"},{"claim_count":10,"coverage":"discussed","id":"A4","source_count":7,"title":"Related evidence: NSABP B-51, A011202 and an unspecified Alliance study"},{"claim_count":13,"coverage":"discussed","id":"A5","source_count":7,"title":"Patient–clinician choices, treatment burden and the systemic-versus-local distinction"},{"claim_count":4,"coverage":"discussed","id":"A6","source_count":1,"title":"Unnamed-trial context: radiotherapy volumes and boosts after primary systemic therapy"}],"counts":{"cited_sources":34,"claims_by_expression_type":{"comparison":6,"interpretation":33,"opinion":21,"primary_context":4,"question":7,"restatement":18,"uncertainty":10,"unspecified":7},"claims_by_kind":{"protocol_statement":1,"publication_statement":8,"source_observation":97},"clinician_statements":24,"evidence_units":107,"findings":7,"organisational_accounts":7,"people_cited":26,"people_identity_verified":17,"people_total":26,"screened_sources":58,"verified_claims":106},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":0,"views":8},"has_counterview":false,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":7,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"The favorable interpretation depends on patient selection and the extent of axillary surgery"},{"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":1,"views":11},"has_counterview":true,"limitations":3,"links":{"context":1,"support":20},"ma_question":true,"named_voices":12,"passages":19,"sources":11,"sources_by_kind":{"commentary":11}},"title":"Low recurrence is persuasive to some authors, but not a shared threshold for changing practice"},{"id":"F3","structure":{"claims":20,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":2,"views":11},"has_counterview":true,"limitations":3,"links":{"context":1,"support":20},"ma_question":true,"named_voices":9,"passages":19,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Late recurrence prompted an explicit, unresolved debate about endocrine treatment and follow-up"},{"id":"F4","structure":{"claims":31,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":12,"views":16},"has_counterview":true,"limitations":3,"links":{"context":2,"support":31},"ma_question":true,"named_voices":17,"passages":26,"sources":16,"sources_by_kind":{"commentary":14,"media":2}},"title":"Response adaptation is interpreted as treatment precision, not chemotherapy replacing radiotherapy"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":5},"has_counterview":true,"limitations":4,"links":{"context":0,"support":14},"ma_question":true,"named_voices":6,"passages":9,"sources":8,"sources_by_kind":{"commentary":8}},"title":"NSABP B-51 and axillary-management evidence are invoked to define what RAPCHEM can support"},{"id":"F6","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":6,"views":10},"has_counterview":true,"limitations":3,"links":{"context":1,"support":22},"ma_question":true,"named_voices":12,"passages":20,"sources":15,"sources_by_kind":{"commentary":13,"media":1,"publication":1}},"title":"Avoiding morbidity motivates support, but measured quality-of-life benefit is not established"},{"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":1},"has_counterview":false,"limitations":4,"links":{"context":1,"support":5},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"An unnamed-trial interview broadens the question to biology-guided volumes and boost doses"}],"medical_affairs_question":"For which combinations of baseline risk, nodal response and axillary surgery is the evidence sufficient to discuss less radiotherapy, and what uncertainty should patients hear?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Surgical treatment and baseline risk limit the favorable interpretation"},{"id":"section-2","level":2,"title":"2. The evidence threshold remains divided: useful guidance versus proof sufficient for practice change"},{"id":"section-3","level":2,"title":"3. Late recurrence was a biological and methodological controversy, not just a request for more years"},{"id":"section-4","level":2,"title":"4. The response-guided concept preserves procedure-specific radiation and the separate indication for chemotherapy"},{"id":"section-5","level":2,"title":"5. Complementary studies are used to address distinct uncertainties"},{"id":"section-6","level":2,"title":"6. Morbidity avoidance is a rationale; patient benefit and implementation remain conditional"},{"id":"section-7","level":2,"title":"7. Unnamed-trial context: post-systemic-therapy volumes and boosts remain subtype-dependent questions"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"observational, cohort, prospective","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":9},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":3}],"id":"T1","label":"Primary endpoint: locoregional recurrence rate"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":10},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":9},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":13}],"id":"T5","label":"Safety and tolerability"}]},"identity":{"accepted_at":"2026-10-31T03:46:59.926639Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T03:58:35Z","record_hash":"f11ec109d89705dab64a522fc63c4dbb4b6faeab9b34f2f3cccb7b75a10be530","release_hash":"ec19a082d93cd2ebe3e572c3f7355107e560cfcb68bebb4f3fa3d72c44b7876c","report_id":"erudio-nct01279304","run_id":"7518dd8f-1c8a-4dae-ae16-a79ee34e8197","schema_version":"5.0","slug":"rapchem-01279304","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"RAPCHEM asks whether nodal-response-guided radiotherapy reduction after chemotherapy and surgery can preserve locoregional control in selected cT1–2N1 breast cancer. Commentary comes from X, LinkedIn and Bluesky posts, as well as podcast interviews. Debate centers on whether low recurrence is enough to change radiotherapy practice, how patient selection and axillary surgery constrain de-escalation, and unresolved questions about endocrine treatment and late recurrence.","meta_description":"58 sources screened · 106 verified statements (24 from clinicians verified by NPI or staff page) from 34 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-5372becbe72b31593f1c"],"id":"F2","paraphrase":"A LinkedIn post examined the role of RAPCHEM’s prospective registry design versus randomized trials in answering radiotherapy de-escalation questions.","publication_caveats":{"reason":"Publication caveats are not stated for this source.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-07-02","title":"Low recurrence is persuasive to some authors, but not a shared threshold for changing practice"},{"cited_claim_ids":["claim-13ae268e15c4934b9c93"],"id":"F1","paraphrase":"A LinkedIn post asked whether the RAPCHEM findings apply after sentinel-node biopsy alone or when axillary surgery is omitted.","publication_caveats":{"reason":"Publication caveats are not stated for this source.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-03-30","title":"The favorable interpretation depends on patient selection and the extent of axillary surgery"}]},"publication":{"approved_at":"2026-10-31T03:58:35Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":58},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","The source search did not run to completion, so some matching discussion may be missing.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a view on short-course radiotherapy versus omission for selected patients and how waiting lists and treatment aversion affect choices.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This is an account of the sources reviewed for this edition, not a representative survey of HCP opinion or a measure of consensus. Organizational communications, presentation relays and reposts must not be counted as independent clinician views.","The 2022 five-year discussions, preliminary NSABP B-51 commentary in December 2023 and 2026 ten-year discussions should not be treated as contemporaneous positions or evidence that any author changed practice.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Some interview statements have no established speaker identity. Equivalent wording in another version of an interview does not authorize assigning the unnamed version to a named person.","The May 2024 unnamed-trial interview contains unclear wording and does not establish a specific initial nodal category. Its views bear on response-adapted radiotherapy but are not RAPCHEM results.","RAPCHEM’s response-defined groups and nonrandomized design do not isolate the causal effect of radiotherapy omission. Surgical intensity, response-related prognosis and variation in delivered radiotherapy qualify favorable interpretations.","Potential reductions in morbidity and improved quality of life are not demonstrated comparative outcomes in the cited discussion; Portugal a speaker explicitly notes the absence of direct quality-of-life data.","Patient totals differ across coverage: some presentation posts report 848, while later ten-year accounts report 838. The report preserves those differences rather than treating them as interchangeable.","A separate protocol was not available among the reviewed sources. Registry methods and publication context do not resolve every treatment-detail question raised in commentary."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":13,"other":0,"podcast":2,"publication":3,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":30,"context":3,"methods":1},"count":34,"evidence_window":{"end":"2026-08-07","start":"2022-08-10"},"retrieval_snapshot":"2026-10-31T03:03:12.416725Z","timeline":[{"count":1,"week":"2022-W32"},{"count":1,"week":"2022-W33"},{"count":1,"week":"2022-W35"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2022-W37"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2026-W02"},{"count":6,"week":"2026-W13"},{"count":4,"week":"2026-W14"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W26"},{"count":2,"week":"2026-W27"},{"count":3,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT01279304:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01279304:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:32058873","quote_policy":"short_quote_link_out"},{"id":"pubmed:35952707","quote_policy":"short_quote_link_out"},{"id":"pubmed:42372742","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3jqvfiysnaxmh5cekxczgqow-3mq7xdr5m2p24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-km6ed4kyyj5hkysfzffqm3vw-3mtgomvmesw2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mtgvdsncwkqbb3wawdcfrwyr-3lqor7o6vi22p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mhuy3o4man2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mhxc67bxxr2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mlyal5mudl2s","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:6975905611104272384","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7003427022286770176","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7138591697499832320","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7139685591411048448","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7414836171089833984","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7442520253223337984","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7444350834445811712","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7444521649548341248","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7463209136516861952","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7463493691177988096","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7476211952588079104","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7478489781258174464","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7480203786821533696","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7481790112469676032","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7483821784144773120","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7491615970650697728","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6a8d98","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b03fa2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1228637209999200256:9d214f26-5386-4138-a2a7-23e0dd0a111c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1556867830083190784:d8ba35b0-1407-4dc8-b5eb-4ec6fb4def98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1556928279151382529:e04af026-5dc7-4f1c-bea1-c8e29d12fa22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1557367189556060160:bfaf182c-0329-45e8-bab9-1c16a560f056","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1558037258241966080:36f20ada-ab2e-4820-b2b0-3dd05e1ecb5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1558983565190303744:aa2e19a8-c2e3-494e-af60-f4c7e91af448","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1559141258332962816:ee61c5dc-ed23-4d0e-a3ea-04877b83f172","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1559178094010716160:d4ecf807-ffc7-4826-844b-bac5835ff326","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1563823826005360640:9ea44777-c8ad-4a76-9ca7-7e119ec558fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1564950603192836099:f671285f-c049-4a0d-ac35-9466107cf7aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565672672125755392:05d761ec-3df6-4575-8702-57657c03c1fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565718092034056194:28a5252f-0bb4-4df3-bb12-cece73078a42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1567219373143724033:549b7298-0463-4274-8d8b-00ffa4486b26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1573307445526646784:aedf4cf1-4d22-4377-b176-2c7b41521294","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1597145649748750336:df4fd118-5917-47da-a724-086f716f2b8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1771086367868563762:937a20bd-fe67-456f-8218-928dda107403","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1771090039960641701:33becf93-bc98-416b-ba1a-607d7c92559c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918556710278475863:6e733e6c-e43e-45ad-9bfe-05e3654fec35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918566971311804727:0a5c8139-2203-40c2-b1a9-2a88ee5bfcbc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929237522401443922:d8a8eee7-b70e-4755-9c69-623a184d3730","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929493658174144856:6eb184f1-b266-41d0-a7e5-3d21b48d65f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2002823067555492167:1912a9f0-0aed-4f57-a6b4-d5872aa6f9bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036745826794451231:c8ad3433-109c-4258-8be4-94753479a16f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036766170632655294:1f4e831c-adc2-4179-91d8-951b6f0d7ae2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036806752742592522:020289c3-9407-4478-b114-a2b9f3c2cfc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037099795920179602:203621fa-6644-413b-936b-0fb6aa9d09e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041587892477423790:22aa1449-cc43-463d-ae4e-f4c4b0714fab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055665986779426967:ce1f1167-7bb2-4f41-88e2-a4e1423d9064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055669365396107564:d04b8ff5-0435-4a91-9b9f-b0dfaa24a704","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055683482261565521:b33fddbf-ee01-4c2a-93a8-6f195f22dfdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071983524765188443:f3686a73-357e-45e5-96eb-71aa5bcf2d25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072028900306059372:47636d2c-4f83-4139-b06b-5dac68ca773a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079142631288840622:f0010684-c493-4631-baee-6add242de48e","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ywDx1NmR5f4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":16,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":33,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":58},"count":58,"evidence_window":{"end":"2026-08-19","start":"2020-02-15"},"retrieval_snapshot":"2026-10-31T03:03:12.416725Z","timeline":[{"count":1,"week":"2020-W07"},{"count":4,"week":"2022-W32"},{"count":3,"week":"2022-W33"},{"count":1,"week":"2022-W34"},{"count":3,"week":"2022-W35"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2022-W37"},{"count":1,"week":"2022-W38"},{"count":2,"week":"2022-W48"},{"count":2,"week":"2023-W49"},{"count":2,"week":"2024-W12"},{"count":1,"week":"2024-W22"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W22"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":7,"week":"2026-W13"},{"count":4,"week":"2026-W14"},{"count":1,"week":"2026-W15"},{"count":4,"week":"2026-W20"},{"count":2,"week":"2026-W21"},{"count":1,"week":"2026-W26"},{"count":3,"week":"2026-W27"},{"count":3,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W34"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RAPCHEM","aliases":["RAPCHEM","Radiotherapy After Primary Chemotherapy for Breastcancer","Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study."],"brief_title":"Radiotherapy After Primary Chemotherapy for Breastcancer","collaborators":["The Netherlands Cancer Institute","Diakonessenhuis, Utrecht"],"conditions":["Breast Cancer"],"enrollment":{"count":851,"type":"ACTUAL"},"interventions":[{"name":"radiation - no radiation see intervention description","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"radiation: see intervention description","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"radiation: see intervention description","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT01279304","official_title":"Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study.","other_names":[{"kind":"also","name":"BOOG 2010-03"}],"overall_status":"COMPLETED","phase":{"reason":"Observational study; registry phases do not apply.","status":"not_applicable"},"primary_completion_date":{"date":"2017-12","type":"ACTUAL"},"primary_endpoints":[{"description":"to evaluate the 5 year locoregional recurrence rate (LRR) in cT1-2cN0-1(cytology/histology and/or positive SN, excluding patients with \\> 3 pathologic axillary nodes on imaging) breast cancer patients, treated with neo-adjuvant chemotherapy, breast surgery, and radiotherapy that is protocolised based on the pathology findings after chemotherapy and definitive surgery (ypTNM stage).","measure":"locoregional recurrence rate","timeFrame":"5 Yr"}],"registered_date":{"date":"2011-01-19","type":"ESTIMATED"},"registry_last_updated":"2022-10-14","registry_url":"https://clinicaltrials.gov/study/NCT01279304","short_name":"RAPCHEM","short_name_basis":"registry_acronym","sponsor":"Maastricht Radiation Oncology","start_date":{"date":"2011-01"},"study_design":"observational, cohort, prospective","study_ids":[{"id":"10-04-10/02","type":"sponsor_study_id"}],"study_type":"OBSERVATIONAL"}}}